Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia
CM McMahon, T Ferng, J Canaani, ES Wang… - Cancer discovery, 2019 - AACR
Gilteritinib is a potent and selective FLT3 kinase inhibitor with single-agent clinical efficacy in
relapsed/refractory FLT3-mutated acute myeloid leukemia (AML). In this context, however …
relapsed/refractory FLT3-mutated acute myeloid leukemia (AML). In this context, however …
[PDF][PDF] Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia
CM McMahon, T Ferng, J Canaani, ES Wang… - 2019 - academia.edu
Gilteritinib is a potent and selective FLT3 kinase inhibitor with single-agent clinical efficacy in
relapsed/refractory FLT3-mutated acute myeloid leukemia (AML). In this context, however …
relapsed/refractory FLT3-mutated acute myeloid leukemia (AML). In this context, however …
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.
CM McMahon, T Ferng, J Canaani, ES Wang… - Cancer …, 2019 - europepmc.org
Gilteritinib is a potent and selective FLT3 kinase inhibitor with single-agent clinical efficacy in
relapsed/refractory FLT3-mutated acute myeloid leukemia (AML). In this context, however …
relapsed/refractory FLT3-mutated acute myeloid leukemia (AML). In this context, however …
[PDF][PDF] Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia
CM McMahon, T Ferng, J Canaani, ES Wang… - 2019 - missionbio.com
Gilteritinib is a potent and selective FLT3 kinase inhibitor with single-agent clinical efficacy in
relapsed/refractory FLT3-mutated acute myeloid leukemia (AML). In this context, however …
relapsed/refractory FLT3-mutated acute myeloid leukemia (AML). In this context, however …
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia
CM McMahon, T Ferng, J Canaani, ES Wang… - Cancer …, 2019 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title/>< jats: p> Gilteritinib is a potent
and selective FLT3 kinase inhibitor with single-agent clinical efficacy in relapsed/refractory …
and selective FLT3 kinase inhibitor with single-agent clinical efficacy in relapsed/refractory …
[PDF][PDF] Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia
CM McMahon, T Ferng, J Canaani, ES Wang… - 2019 - pdfs.semanticscholar.org
Gilteritinib is a potent and selective FLT3 kinase inhibitor with single-agent clinical efficacy in
relapsed/refractory FLT3-mutated acute myeloid leukemia (AML). In this context, however …
relapsed/refractory FLT3-mutated acute myeloid leukemia (AML). In this context, however …
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia
CM McMahon, T Ferng, J Canaani… - Cancer …, 2019 - pubmed.ncbi.nlm.nih.gov
Gilteritinib is a potent and selective FLT3 kinase inhibitor with single-agent clinical efficacy in
relapsed/refractory FLT3-mutated acute myeloid leukemia (AML). In this context, however …
relapsed/refractory FLT3-mutated acute myeloid leukemia (AML). In this context, however …